Chung-Sheng Shi1,2, Jhy-Ming Li1, Chih-Chien Chin1,3, Yi-Hung Kuo1,3, Ying-Ray Lee4, Yun-Ching Huang5,2. 1. Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan, R.O.C. 2. Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Chiayi, Taiwan, R.O.C. 3. Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chiayi, Taiwan, R.O.C. 4. Department of Medical Research, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan, R.O.C. yingray.lee@gmail.com chrishyc@gmail.com. 5. Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan, R.O.C. yingray.lee@gmail.com chrishyc@gmail.com.
Abstract
BACKGROUND/AIM: Evodiamine, an indole alkaloid derived from Evodia rutaecarpa, exhibits pharmacological activities including vasodilatation, analgesia, anti-cardiovascular disease, anti-Alzheimer's disease, anti-inflammation, and anti-tumor activity. MATERIALS AND METHODS: This study analyzes the anti-tumor effects of evodiamine on cellular growth, tumorigenesis, cell cycle and apoptosis induction of human urothelial cell carcinoma (UCC) cells. RESULTS: The present study showed that evodiamine significantly inhibited the proliferation of UCC cells in a dose- and time-dependent manner. Also, evodiamine suppressed the tumorigenesis of UCC cells in vitro. Moreover, evodiamine caused G2/M cell-cycle arrest and induced caspase-dependent apoptosis in UCC cells. Finally, we demonstrated that evodiamine exhibits better cytotoxic than 5-fluorouracil, a clinical chemotherapeutic drug, for UCC cells. CONCLUSION: Evodiamine induces growth inhibition, tumorigenesis suppression, cell-cycle arrest, and apoptosis induction in human UCC cells. Therefore, this agent displays a therapeutic potential for treating human UCC cells and is worthy for further investigation. Copyright
BACKGROUND/AIM: Evodiamine, an indole alkaloid derived from Evodia rutaecarpa, exhibits pharmacological activities including vasodilatation, analgesia, anti-cardiovascular disease, anti-Alzheimer's disease, anti-inflammation, and anti-tumor activity. MATERIALS AND METHODS: This study analyzes the anti-tumor effects of evodiamine on cellular growth, tumorigenesis, cell cycle and apoptosis induction of humanurothelial cell carcinoma (UCC) cells. RESULTS: The present study showed that evodiamine significantly inhibited the proliferation of UCC cells in a dose- and time-dependent manner. Also, evodiamine suppressed the tumorigenesis of UCC cells in vitro. Moreover, evodiamine caused G2/M cell-cycle arrest and induced caspase-dependent apoptosis in UCC cells. Finally, we demonstrated that evodiamine exhibits better cytotoxic than 5-fluorouracil, a clinical chemotherapeutic drug, for UCC cells. CONCLUSION:Evodiamine induces growth inhibition, tumorigenesis suppression, cell-cycle arrest, and apoptosis induction in human UCC cells. Therefore, this agent displays a therapeutic potential for treating human UCC cells and is worthy for further investigation. Copyright
Authors: Jamie R Friedman; Nicholas A Nolan; Kathleen C Brown; Sarah L Miles; Austin T Akers; Kate W Colclough; Jessica M Seidler; John M Rimoldi; Monica A Valentovic; Piyali Dasgupta Journal: J Pharmacol Exp Ther Date: 2017-12-15 Impact factor: 4.030
Authors: Dirk Rades; Liesa Dziggel; Lisa Manig; Stefan Janssen; Mai Trong Khoa; Vuong Ngoc Duong; Vu Huu Khiem; Steven E Schild Journal: In Vivo Date: 2018 May-Jun Impact factor: 2.155